Provention Bio’s new injectable drug, which was recommended by an FDA committee for approval on May 25, 2021, has had a tumultuous journey through the FDA application process. Studies showed that teplizumab can delay the onset of type 1 diabetes – for people already at high risk – for two years or more. Continue Reading »